Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary? – PubMed
The editorial on the MAGNITUDE study – combination PARP inhibitor + abiraterone. Is biomarker testing necessary? They say yes.